Kisho

The Fabry disease treatment market is set to grow significantly by 2031, driven by Japan's early-access framework and South Korea's insurance coverage for enzyme replacement therapy. Increased clinical trial activity and expanded screening are identifying more patients, while innovative therapies are enhancing treatment options.

Japan's early-access framework, South Korea's insurance coverage for enzyme replacement therapy, and China's expanded rare disease reimbursement policies are accelerating treatment availability. Growing clinical trial activity and healthcare infrastructure investment in India and Southeast ... Japan's early-access framework, South Korea's insurance coverage for enzyme replacement therapy, and China's expanded rare disease reimbursement policies are accelerating treatment availability. Growing clinical trial activity and healthcare infrastructure investment in India and Southeast Asia are expected to create additional opportunities through 2031. Expanded screening is identifying more Fabry patients, while gene, mRNA and oral therapies offer less burdensome, personalized care, with strong... Conversely, orphan-drug incentives, fast-track regulatory designations, and increased healthcare spending on rare diseases are expected to support future market expansion. Enzyme Replacement Therapy Maintains Market Leadership · Enzyme replacement therapy accounted for 67.85% of Fabry disease treatment market revenue in 2025. Its established safety profile and extensive clinical use continue to support its position as a primary treatment approach. North America generated 42.85% of global market revenue in 2025, supported by newborn screening, specialist treatment centers, established reimbursement systems, and active clinical trial recruitment. Regulatory pathways offering priority review and breakthrough designations are also encouraging faster adoption of innovative Fabry disease therapies across the United States and Canada.

Treatment & Clinical News2 months agoRead at source →

Original title: “Fabry Disease Treatment Market 2026-2031 - Growth Driven by Increasing Adoption of Enzyme Replacement Therapy”

Kisho

Not rare diseases news,
news about your rare disease.

Earlier

A recent study provides a longitudinal assessment of retinal phenotypes in patients with Fabry disease receiving enzyme replacement and chaperone therapy. This research enhances understanding of the disease's impact on retinal health over time.

A recent case report highlights early neuropathic symptoms as indicators of pediatric Fabry disease. This discovery may enhance early diagnosis and intervention strategies for affected children.

A recent study explores epigenetic aging and methylation changes in Anderson-Fabry disease, providing insights into the disease's biological mechanisms. This research could inform future therapeutic strategies and patient management.

A 9-year case report highlights long-term cardiac remodeling in a heterozygote woman with Fabry disease undergoing migalastat therapy. This study provides insights into the chronic effects of treatment on cardiac health in Fabry patients.

A multicenter Italian study investigates the prevalence of GLA variants in Fabry disease among patients with parapelvic cysts. The findings contribute to understanding the genetic underpinnings of this rare condition.

Biotech funding rises 75% this year as M&A activity continues By Investing.com

PTC takes a chance on Sangamo’s Fabry disease gene therapy

Bankrupt Sangamo offloads assets to Lilly, PTC in $161M sale

A new study highlights the paradoxical native T1 elevation in triglyceride deposit cardiomyovasculopathy, which may lead to misdiagnosis when compared to Fabry disease. This research underscores the need for careful differentiation between these two conditions in clinical settings.

Recent research highlights myocardial inflammation and scar expansion in patients with Anderson-Fabry disease, shedding light on cardiac complications associated with this condition. Understanding these mechanisms may inform future therapeutic strategies.

Recent research highlights the cardiac and neurologic complications associated with Fabry disease, emphasizing the need for comprehensive management strategies. This study contributes to the understanding of the disease's systemic effects.

Recent research highlights the need for enhanced heart rhythm monitoring in patients with Fabry disease cardiomyopathy. This study emphasizes the potential for improved patient outcomes through better management of cardiac symptoms.

A systematic literature review evaluates the impact of antidrug antibodies on efficacy and safety outcomes in patients with Fabry disease undergoing enzyme replacement therapy. This research provides insights that could influence treatment strategies for this rare condition.

A study published in PubMed examines real-world outcomes of Fabry disease treatment in Italian excellence centers. The findings contribute to understanding disease management and patient care in this rare condition.

A multicenter study on Fabry disease highlights the risk of sudden cardiac death and major arrhythmic events, emphasizing the need for improved risk stratification in affected patients. The findings could inform future clinical practices and patient management strategies.

A case report highlights the impact of migalastat therapy on corneal deposits in a female patient with Fabry disease. This study contributes to the understanding of treatment effects in rare diseases.

A recent study explores the correlation of retinal vascular characteristics with laboratory and ocular findings in Fabry disease, aiming to identify potential ocular diagnostic biomarkers. This research could enhance diagnostic accuracy for patients with Fabry disease.

The Italian Fabry disease neurological working group has released consensus statements on neurological management and outcome measures for Fabry disease. These guidelines aim to standardize care and improve patient outcomes in this rare condition.

Researchers in China developed and validated a self-management efficacy questionnaire specifically for patients with Fabry disease. This tool aims to enhance patient engagement and management of their condition.

Not rare diseases news,news about your rare disease.